Ophthalmic Compositions Blocking Viral Entry via ACE2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections, particularly those involving the ACE2 receptor like COVID-19, lack effective and safe methods for prevention and treatment, especially considering the ocular surface as a potential entry point for viral transmission.
Innovation Solution
Development of ophthalmic, inhalation, or topical compositions containing hydroxychloroquine or chloroquine, zinc ions, azithromycin, and ACE2 inhibitors, along with iota-carrageenan, which are administered directly to the eye, nose, or mouth to block viral binding to ACE2 receptors, providing a localized and potentially more effective treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic treatment is used to treat viral infections, then the treatment can reach the virus throughout the body, but systemic side effects increase
Solution Approach 1:
The patent divides the treatment approach into localized ocular administration rather than systemic administration. By segmenting the treatment to target specifically the ocular surface where viral entry occurs, the patent achieves effective viral inhibition while avoiding widespread systemic side effects associated with oral or intravenous medications.
Solution Approach 2:
The patent applies treatment locally at the ocular surface where the virus enters through ACE2 receptors. This localized application ensures high concentration of antiviral agents exactly where needed (at the viral entry point) while minimizing exposure and side effects in other body systems.
2Reliability
If the ocular surface is targeted for viral prevention, then direct blocking of viral entry is achieved, but new treatment methods are required
Solution Approach 1:
The patent employs composite ophthalmic formulations containing multiple active ingredients (hydroxychloroquine, chloroquine, azithromycin, and other antiviral agents) combined in a single eye drop or ointment formulation. This composite approach provides multi-target viral inhibition while maintaining ease of ocular administration, balancing effectiveness with formulation manageability.
3Adaptability or versatility
If existing treatments are used for viral infections, then treatment options are available, but effectiveness against ACE2-receptor viruses is insufficient
Solution Approach 1:
The patent modifies the approach by selecting and combining specific antiviral agents (hydroxychloroquine, chloroquine, azithromycin) that have demonstrated activity against ACE2-receptor viruses like SARS-CoV-2. By adjusting the pharmacological parameters through combination therapy and ocular administration, the patent achieves enhanced effectiveness against this specific virus class while maintaining treatment accessibility.
Data Source
AI summary
The present invention relates to the field of viral infection therapeutic treatments and prophylactic treatments. In particular, provided are methods of treating or preventing viral infections, such as viral infections resulting from entering or infecting a subject via association with or binding to an ACE2 receptor in the subject, with ophthalmic composition, inhalation compositions, and/or topical compositions. In particular, provided are methods of treating or preventing viral infections, such as coronavirus infections, for example COVID-19 infections, in a subject exposed to, or prior to exposure to a coronavirus, for example a COVID-19, by administering an ophthalmic composition, an inhalation composition, and/or a topical composition.